International Journal of Molecular Medical Science, 2025, Vol.15, No.5, 235-243 http://medscipublisher.com/index.php/ijmms 243 Nielsen S., Lamberts M., Nouhravesh N., Jensen M., Strange J., Gislason G., McGettigan P., and Holt A., 2024, Temporal trend of first-line drug choice and treatment continuity for hypertension among citizens 75 years or over-a register-based cohort study, International Journal of Cardiology, 408: 132137. https://doi.org/10.1016/j.ijcard.2024.132137 Blazek O., and Bakris G., 2023, Slowing the progression of diabetic kidney disease, Cells, 12(15): 1975. https://doi.org/10.3390/cells12151975 Pappoe L., and Winkelmayer W., 2010, ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus, Drugs and Aging, 27: 87-94. https://doi.org/10.2165/11316430-000000000-00000 Srivastav S., Julie E., Goodwin K., Kanasaki and Koya D., 2020, Inhibition of angiotensin-converting enzyme ameliorates renal fibrosis by mitigating DPP-4 level and restoring antifibrotic microRNAs, Genes, 11(2): 211. https://doi.org/10.3390/genes11020211 Tada K., Nakano Y., Takahashi K., Hiyamuta H., Watanabe M., Ito K., Yasuno T., Abe M., Satoh A., Kawazoe M., Maeda T., Yoshimura C., Kosuke M., and Arima H., 2024, Current use of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors for hypertension in patients with chronic kidney disease with proteinuria: a cross-sectional study based on real-world data, Hypertension Research, 48(1): 244-255. https://doi.org/10.1038/s41440-024-01896-0 Tian B., Deng Y., Cai Y., Han M., and Xu G., 2021, Efficacy and safety of combination therapy with sodium-glucose transporter 2 inhibitors and renin-angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis, Nephrology Dialysis Transplantation, 37(4): 720-729. https://doi.org/10.1093/ndt/gfab048 Kratky V., Vaňourková Z., Sýkora M., Bacova B.S., Hrušková Z., Kikerlová S., Husková Z., and Kopkan L., 2021, AT1 receptor blocker but not an ACE inhibitor prevents kidneys from hypoperfusion during congestive heart failure in normotensive and hypertensive rats, Scientific Reports, 11(1): 4271. https://doi.org/10.1038/s41598-021-83906-6 Wang X., and He B., 2024, Endothelial dysfunction: molecular mechanisms and clinical implications, MedComm., 5(8): e651. https://doi.org/10.1002/mco2.651 Xu L.H., and Fang K.Y., 2025, Personalized dietary and pharmacological management of hyperuricemia in patients with chronic kidney disease (CKD), International Journal of Clinical Case Reports, 15(4): 171-181. https://doi.org/10.5376/ijccr.2025.15.0018 Zaslavskaya R., Krivchikova L., and Teyblyum M., 2022, Assessment of the comparative efficiency of treatment with angiotensin-converting enzyme inhibitor and angiotensin II receptor blockers in patients who are old and senile with stage 3 grade 2-3 hypertension, Medical Journal of the Russian Federation, 28(1): 57-63. https://doi.org/10.17816/medjrf108902 Zhang M., Liu W., Dai H., Jiang H., Zhao Q., Liu W., Rui H., and Liu B., 2025., Heterogeneity of renal endothelial cells interact with neighboring cells and endothelial injury in chronic kidney disease: mechanisms and therapeutic implications, International Journal of Medical Sciences, 22: 2103-2118. https://doi.org/10.7150/ijms.108299 Zhang Y., He D., Zhang W., Xing Y., Guo Y., Wang F., Jia J., Yan T., Liu Y., and Lin S., 2020., ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: a network meta-analysis of randomised clinical trials, Drugs, 80: 797-811. https://doi.org/10.1007/s40265-020-01290-3 Zhao M., Wang R., Yu Y., Chang M., Ma S., Zhang H., Qu H., and Zhang Y., 2021, Efficacy and safety of angiotensin-converting enzyme inhibitor in combination with angiotensin-receptor blocker in chronic kidney disease based on dose: a systematic review and meta-analysis, Frontiers in Pharmacology, 12: 638611. https://doi.org/10.3389/fphar.2021.638611 Zheng C., Wang J., Chen T., Wu Y., Wu Y., Lin H., Chiu S., Chang T., Zheng J., Chu N., Lin Y., Su S., Lu K., Chen J., Sung F., Lee C., Yang Y., Hwang S., Wang M., Hsu Y., Chiou H., Kao S., Wu M., and Lin Y., 2019, Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population, Scientific Reports, 9(1): 2694. https://doi.org/10.1038/s41598-019-38991-z
RkJQdWJsaXNoZXIy MjQ4ODYzNA==